Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Bioequivalence of MSB11455 (Stimufend) vs Neulasta in Healthy Adults
NCT03251248Phase 1Completed
- Sponsor
- Fresenius Kabi
- Start
- Aug 2017
- Primary completion
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Stimufend OBI in febrile neutropenia (FN) (2 arms), sponsored by Fresenius Kabi. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration, Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity and 3 more. Started Aug 2017; status: completed.
02
Drugs
Stimufend OBI
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT03251248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251248.